Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01493726 · ClinicalTrials.gov registry record · Phase 1

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

A Phase 1 study of Schizophrenia, sponsored by Alkermes.

Completed
Registry status
Phase 1
Development phase
88
Enrollment target
6
Study locations

NCT01493726 is a Phase 1 study of Schizophrenia that has completed, run by Alkermes. The registered enrollment target is 88 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01493726, a Phase 1 study of Schizophrenia, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 1
Development phase
88 participants
Enrollment target
6
Study locations

Study Summary

This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG ALKS 9072, Low dose
  • DRUG ALKS 9072, Med dose
  • DRUG ALKS 9072, High dose

Study Locations (6)

Georgia

  • Alkermes Investigational Site - Atlanta

Illinois

  • Alkermes Investigational Site - Hoffman Estates

Missouri

  • Alkermes Investigational Site - St Louis

New Jersey

  • Alkermes Investigational Site - Willingboro

Pennsylvania

  • Alkermes Investigational Site - Philadelphia

Texas

  • Alkermes Investigational Site - Irving

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2011-12
Est. Completion 2013-06
Phase Phase 1

Sponsor

Alkermes

66 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01493726

The ClinicalTrials.gov registry entry for NCT01493726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT01493726 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT01493726 about?

NCT01493726 is a clinical study titled "A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia". This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.

What is the current status of trial NCT01493726?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2011-12. Estimated completion is 2013-06.

What conditions does trial NCT01493726 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT01493726?

The interventions under investigation include: Placebo (DRUG), ALKS 9072, Low dose (DRUG), ALKS 9072, Med dose (DRUG), ALKS 9072, High dose (DRUG).

Who is sponsoring clinical trial NCT01493726?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01493726 being conducted?

This trial has 6 study locations across Georgia, Illinois, Missouri, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.